Abstract
Despite the recent advances in our understanding of the role of lipids, metabolites, and related enzymes in mediating kidney injury, there is limited integrated multi-omics data identifying potential metabolic pathways driving impaired kidney function. The limited availability of kidney biopsies from living donors with acute kidney injury has remained a major constraint. Here, we validated the use of deceased transplant donor kidneys as a good model to study acute kidney injury in humans and characterized these kidneys using imaging and multi-omics approaches. We noted consistent changes in kidney injury and inflammatory markers in donors with reduced kidney function. Neighborhood and correlation analyses of imaging mass cytometry data showed that subsets of kidney cells (proximal tubular cells and fibroblasts) are associated with the expression profile of kidney immune cells, potentially linking these cells to kidney inflammation. Integrated transcriptomic and metabolomic analysis of human kidneys showed that kidney arachidonic acid metabolism and seven other metabolic pathways were upregulated following diminished kidney function. To validate the arachidonic acid pathway in impaired kidney function we demonstrated increased levels of cytosolic phospholipase A2 protein and related lipid mediators (prostaglandin E2) in the injured kidneys. Further, inhibition of cytosolic phospholipase A2 reduced injury and inflammation in human kidney proximal tubular epithelial cells in vitro. Thus, our study identified cell types and metabolic pathways that may be critical for controlling inflammation associated with impaired kidney function in humans.
| Original language | English |
|---|---|
| Pages (from-to) | 85-97 |
| Number of pages | 13 |
| Journal | Kidney International |
| Volume | 106 |
| Issue number | 1 |
| Early online date | 29 Feb 2024 |
| DOIs | |
| Publication status | Published - 1 Jul 2024 |
Bibliographical note
We are grateful to the donors, donor families, and NHS Blood and Transplant service and the Cambridge Biorepository for Translational Medicine (CBTM) for access to human samples; Karolina Nilsson (Medicinal Chemistry, AstraZeneca) for providing the cytosolic phospholipase A2 inhibitor; and Julia Lindgren (Discovery Sciences, AstraZenca) for coordinating the RNA-sequencing workflow.Data Availability Statement
All data are presented in the article and any analysis methods described. Transcriptomic data can be accessed at Gene Expression Omnibus using GSE217427. Serum and kidney lipidomics data can be accessed at https://doi.org/10.6084/m9.figshare.24990996.v1 and https://doi.org/10.6084/m9.figshare.24991002.v1. Kidney metabolomics data can be accessed at https://doi.org/10.6084/m9.figshare.24990999.v1. Data used for imaging mass cytometry can be accessed at https://doi.org/10.6084/m9.figshare.24999374.v1.Funding
This work was funded from a research collaboration grant by AstraZeneca.
Keywords
- arachidonic acid
- kidney damage
- kidney inflammation
- imaging mass cytometry
- lipidomics
- metabolic pathways